SLC5A1 and diabetes mellitus: Preclinical and initial clinical trials have demonstrated that SGLT-1 inhibitors, either alone or in combination with SGLT-2 inhibitors, effectively ameliorate postprandial hyperglycemia in patients with diabetes (8), underscoring the indispensable role of SGLT-1 in glucose metabolism.